Actinium Pharmaceuticals Inc (ATNM) USD0.001

Sell:$1.53Buy:$1.56$0.04 (2.53%)

Prices delayed by at least 15 minutes
Sell:$1.53
Buy:$1.56
Change:$0.04 (2.53%)
Prices delayed by at least 15 minutes
Sell:$1.53
Buy:$1.56
Change:$0.04 (2.53%)
Prices delayed by at least 15 minutes

Company Information

About this company

Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Key people

Sandesh Seth
Chairman of the Board, Chief Executive Officer
Steve O'Loughlin
Chief Financial Officer, Corporate Secretary
June S. Almenoff
Independent Director
Jeffrey W. Chell
Independent Director
C. David Nicholson
Lead Independent Director
Ajit S. Shetty
Independent Director
Richard I. Steinhart
Independent Director
Click to see more

Key facts

  • EPIC
    ATNM
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00507W2061
  • Market cap
    $49.91m
  • Employees
    37
  • Shares in issue
    31.20m
  • Exchange
    Nyse American LLC
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.